KMT2A and acute myeloid leukemia: Indeed, several preclinical studies found that the combination of menin and DOT1L inhibition displaces KMT2A-FPs from chromatin more quickly than single-agent treatment, and H3K79me2/3 at HOX and MEIS loci is decreased far more significantly after combination treatment in both MLL-r and NPM1c AML.